Introduction
============

Osteoarthritis is a common joint disease mainly characterized by the degeneration and breakdown of articular cartilage, the formation of osteophytes and subchondral cysts, and the thickening of subchondral bone ([@b1-etm-0-0-8488]). Articular cartilage is a resilient and smooth tissue that covers and protects the ends of bones in joints, and primarily consists of a dense extracellular matrix with no blood vessels, lymphatic vessels or nerves, with a sparse chondrocyte population ([@b2-etm-0-0-8488],[@b3-etm-0-0-8488]).

The extracellular matrix is a multifaceted meshwork of proteoglycans, polysaccharides and proteins secreted by resident supporting cells. The extracellular matrix not only represents a critical structural component of articular cartilage, but is also involved in the pathological degradation of articular cartilage ([@b4-etm-0-0-8488]). Physical and biochemical alterations in the extracellular matrix may elicit numerous signaling events by communicating with the intracellular cytoskeleton, stimulating chondrocyte responses and thus inducing osteoarthritis ([@b7-etm-0-0-8488]). The dynamic remodeling and homeostasis of the extracellular matrix is regulated by a variety of proteinases, especially proteinases in the matrix metalloproteinase (MMP) family ([@b10-etm-0-0-8488],[@b11-etm-0-0-8488]).

Facet joint osteoarthritis (FJOA) is a common form of osteoarthritis that occurs in the facet joints located in the posterior aspect of the vertebral column ([@b12-etm-0-0-8488]). However, to the best of our knowledge, FJOA is not as well studied as other forms of osteoarthritis, such as hip osteoarthritis and knee osteoarthritis. Efforts have been made to examine the anatomy, biomechanics, epidemiology and clinical manifestations of FJOA ([@b13-etm-0-0-8488]). The expression of key molecules in the degenerative process of facet joints such as MMP13, tumor necrosis factor-a and interleukin-6 have also been identified ([@b14-etm-0-0-8488]). A previous study determined the molecular changes in FJOA by collecting human facet joint tissues from healthy controls and patients with FJOA and conducting transcriptome sequencing ([@b15-etm-0-0-8488]).

The current study investigated the expression profiles of genes in healthy controls and patients with FJOA by filtering genes with the most significant fold-changes and screening the most enriched Gene Ontology (GO) categories. Analysis results showed that MMP12, a member of the MMP family, was the most downregulated gene in FJOA. In addition, many enriched GO categories were related to the extracellular matrix. Therefore, the canonical signaling pathway 'inhibition of matrix metalloproteinases' was investigated through the joint use of Ingenuity Pathway Analysis (IPA) software, heatmap and hierarchical cluster analysis, and reverse transcription-quantitative PCR (RT-qPCR) validation to study the involvement of MMPs in FJOA.

Materials and methods
=====================

### Facet joint tissue collection and transcriptome sequencing

Human facet joint tissues were collected from 48 patients with FJOA (FJOA group) and 10 healthy patients with vertebral fractures (control group) as previously described ([@b15-etm-0-0-8488]). Magnetic resonance imaging was applied to determine the degree of cartilage degeneration. The facet joint tissues of patients in the FJOA group were of Grade 2 (moderate degeneration) and Grade 3 (severe degeneration), while the facet joint tissue of patients in the control group was of Grade 0 (normal) and Grade 1 (mild degeneration) ([@b16-etm-0-0-8488]). Patients with infection, inflammatory diseases or autoimmune diseases were excluded from the current study. The present study was ethically approved by the Human Ethics Committee of the Second Affiliated Hospital of Nantong University. All participants provided written informed consent.

Facet joint tissues from the FJOA and control groups were divided into three parts for technical repetitions for subsequent RNA isolation and sequencing experiments. Total RNA was extracted using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. Extracted total RNA was used to fragment RNA and synthesize cDNA. A cDNA library was amplified and sequenced using a Hiseq X Ten sequencing platform (Illumina, Inc.) to produce raw reads. Dirty reads were filtered to obtain clean reads. Clean reads were then mapped to the reference genome using TopHat v2.1.1 (<https://ccb.jhu.edu/software/tophat/index.shtml>) ([@b17-etm-0-0-8488],[@b18-etm-0-0-8488]).

### Bioinformatics analysis

Transcriptome sequencing data were used to identify the fragments per kilobase of transcript per million mapped reads (FPKM) values of each gene. The FPKM values of genes in the FJOA group were compared with the FPKM values in the control group to screen differentially expressed genes with a fold-change \>2 or \<-2 (log~2~ ratio \>1 or \<-1) and a q-value (adjusted P-value) \<0.05. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) 6.7 (<https://david.ncifcrf.gov/>) was used to enrich differentially expressed genes to GO categories ([@b19-etm-0-0-8488]). IPA software (2018 release Qiagen, Inc.) was used to analyze the canonical signaling pathway 'inhibition of matrix metalloproteinases'. Heatmap and hierarchical cluster analyses were performed using R v2.13.0 (<https://www.r-project.org/>) to display the expression patterns of differentially expressed genes.

### RT-qPCR

RT-qPCR was conducted to validate transcriptome sequencing outcomes. RNA samples were first reverse transcribed to cDNA using the PrimeScript RT Reagent kit (Takara Biotechnology Co., Ltd.) according to the manufacturer\'s protocol. qPCR was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd) on a StepOnePlus Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for the PCR: Initial denaturation at 95˚C for 5 min; 40 cycles of 95˚C at 30 sec, 45 sec at 56.5˚C and 72˚C for 30 sec; and a final extension at 72˚C for 5 min. The relative expression of target genes MMP7, disintegrin and metalloproteinase domain-containing protein 12 (ADAM12), tissue inhibitor of metalloproteinases 3 (TIMP3) and TIMP4 were calculated using the 2^-ΔΔCq^ method with GAPDH as the internal reference gene ([@b22-etm-0-0-8488]). The sequences of primers pairs used in the qPCR are listed in [Table I](#tI-etm-0-0-8488){ref-type="table"}.

### Statistical analysis

Data are presented as the mean ± SEM and were analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc.). Student\'s t-test was used to compare differences between the FJOA and control groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of the most differentially expressed genes in FJOA

Previous transcriptome sequencing determined the expression levels of \>19,000 genes in human facet joint tissues in both FJOA and control groups ([@b15-etm-0-0-8488]). To obtain a global view of the expression patterns of identified genes, the Heatmap function in the software platform R (v.2.13.0) was used to draw a heatmap of gene expression ([Fig. 1](#f1-etm-0-0-8488){ref-type="fig"}). The Euclidean distance was calculated using the Hierarchical Clustering module from GenePattern (<https://software.broadinstitute.org/cancer/software/genepattern/>) to cluster the identified genes ([Fig. 1](#f1-etm-0-0-8488){ref-type="fig"}) ([@b23-etm-0-0-8488]). Parallelizing hierarchical clustering methods were used to study the gene expression profiles in the three control group replicates (CTRL1, CTRL2 and CTRL3) and three FJOA group replicates (FJOA1, FJOA2 and FJOA3) ([Fig. 1](#f1-etm-0-0-8488){ref-type="fig"}). Compared with genes in the control group, a smaller number of genes in the FJOA group were upregulated while a relatively large number of genes were downregulated.

A detailed investigation of these differentially expressed genes showed that the expression level of the most upregulated gene in FJOA, corticotropin releasing hormone receptor 1 (CRHR1), was elevated \>28.8 fold (log~2~ ratio=4.85) compared with the control group. The expression level of the most downregulated gene, MMP12, was reduced to \~1/14 of its expression level compared with the control group (log~2~ ratio=-3.86). The 10 most upregulated and downregulated genes in FJOA are listed in [Table II](#tII-etm-0-0-8488){ref-type="table"}.

### Identification of most enriched GO categories in FJOA

To have a better understanding of the molecular mechanisms underlying FJOA, the DAVID database was used to group differentially expressed genes into GO biological processes, molecular functions and cellular components ([Fig. 2](#f2-etm-0-0-8488){ref-type="fig"}). The ten most enriched GO biological processes were associated with the response of the organism ('response to stress' and 'response to stimulus'), immune response ('regulation of immune system process', 'positive regulation of immune system process', 'immune system process', 'immune response' and 'defense response') and cellular behaviors ('cell adhesion', 'cell activation' and 'biological adhesion'). The significant involvement of the immune response was consistent with the high expression of CRHR1 observed in FJOA tissue, as CRHR1 is essential for the activation of various signaling pathways that regulate the immune response. The ten most enriched GO molecular functions were mainly related to molecular binding, while the ten most enriched GO cellular components included various components, especially those involving the extracellular matrix such as 'proteinaceous extracellular matrix', 'extracellular space', 'extracellular region part', 'extracellular region' and 'extracellular matrix'.

### Analysis of the canonical signaling pathway 'inhibition of matrix metalloproteinases'

GO cellular component analysis showed that the extracellular matrix was highly associated with FJOA. In addition, MMP12, a gene that encodes for an enzyme involved in the breakdown of the extracellular matrix, was most significantly downregulated in FJOA. The results of the bioinformatics analysis suggested that dysregulated MMPs and the resulting modulated extracellular matrix might be critical in the pathological process of FJOA. Therefore, IPA bioinformatics analysis was performed to identify the involvement of the canonical signaling pathway 'inhibition of matrix metalloproteinases' in FJOA.

The schematic diagram of the canonical signaling pathway 'inhibition of matrix metalloproteinases' is shown in [Fig. 3](#f3-etm-0-0-8488){ref-type="fig"}. MMPs are calcium-dependent zinc-containing endopeptidases that are critical for the modulation of both cell-cell and cell-extracellular matrix interactions ([@b24-etm-0-0-8488]). These MMPs are tightly regulated at multiple levels, including gene transcription, enzyme activation and inhibitor inactivation ([@b25-etm-0-0-8488]). TIMPs are a family of protease inhibitors comprising TIMP1, TIMP2, TIMP3 and TIMP4. TIMPs form non-covalent bonds with the latent and active forms of MMPs with a 1:1 stoichiometry and thus inhibit the activity of MMPs ([@b26-etm-0-0-8488]). Members of the ADAM family, such as ADAM10, ADAM12 and ADAM13 also regulate cell adhesion and mediate the extracellular matrix ([@b27-etm-0-0-8488]) ([Fig. 3](#f3-etm-0-0-8488){ref-type="fig"}).

Upregulated and downregulated genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases' in FJOA are labeled in red and green, respectively ([Fig. 3](#f3-etm-0-0-8488){ref-type="fig"}). The expression levels of genes in the pathway are shown in [Table III](#tIII-etm-0-0-8488){ref-type="table"}. Heatmap and relevant hierarchical clustering analyses were performed to illustrate the expression levels of genes in the FJOA and control groups ([Fig. 4](#f4-etm-0-0-8488){ref-type="fig"}). Most members of the MMP family (including MMP12, MMP9, MMP3, MMP16, MMP7, MMP8 and MMP25) were significantly downregulated in FJOA compared with controls. Meanwhile, MMP23B was upregulated and the expression levels of other members of the MMP family were not significantly altered compared with controls. ADAM12 and MMP inhibitors TIMP3 and TIMP4 were upregulated in FJOA compared with controls.

### Validation using RT-qPCR

RT-qPCR experiments were further conducted to measure the expression of genes in FJOA and control groups in order to validate transcriptome sequencing results. Representative genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases', MMP7, ADAM12, TIMP3 and TIMP4 were selected for RT-qPCR experiments ([Fig. 5](#f5-etm-0-0-8488){ref-type="fig"}). Consistent with the transcriptome sequencing results, the expression levels of MMP7 were significantly downregulated in the FJOA group compared with the control group. By contrast, the expression levels of ADAM12, TIMP3 and TIMP4 were significantly higher in the FJOA group as compared with the control group ([Fig. 5](#f5-etm-0-0-8488){ref-type="fig"}).

Discussion
==========

In the current study, transcriptome sequencing outcomes from human facet joint tissues in FJOA patients and healthy controls were analyzed. The ten most significantly upregulated and downregulated genes were identified and the ten most enriched GO biological processes, molecular functions and cellular components were categorized. The analytical results showed that the extracellular matrix was robustly involved in the genetic changes involved in FJOA. MMP12, a calcium-dependent zinc-containing endopeptidase capable of degrading the extracellular matrix, was the most downregulated gene in FJOA. CRHR1, which encodes a G-protein coupled receptor that binds neuropeptides of the corticotropin releasing hormone family that are major regulators of the hypothalamic-pituitary-adrenal pathway, was the most differentially expressed gene in FJOA. From a gene expression aspect, the results suggested that modulation of the extracellular matrix is a critical biological process in FJOA, and the CRHR1-regulated immune response might be critical in the development of FJOA. Treatments targeting CRHR1 and MMP might be potential therapeutic methods. Therefore, gene changes in the canonical signaling pathway 'inhibition of matrix metalloproteinases' were examined. Heatmap analysis and RT-qPCR experiments illustrated that several genes in 'inhibition of matrix metalloproteinases', especially MMPs and TIMPs, were dysregulated in FJOA.

The extracellular matrix is a non-cellular meshwork of extracellular molecules that provides a three-dimensional physical and mechanical support for surrounding cells ([@b28-etm-0-0-8488]). The extracellular matrix is highly dynamic and is continuously remodeled by matrix-degrading enzymes under various physiological and pathological conditions, including cell migration, cell differentiation, cell growth, wound healing and fibrosis ([@b28-etm-0-0-8488]). The remodeling of the extracellular matrix is principally mediated by MMPs ([@b32-etm-0-0-8488],[@b33-etm-0-0-8488]). Changes in the composition and structure of the extracellular matrix, such as loss of proteoglycans, mineralization of the extracellular matrix and accumulation of malformed extracellular matrix are hallmarks of osteoarthritis ([@b8-etm-0-0-8488],[@b34-etm-0-0-8488]). The present study showed that genes coding for many MMPs were downregulated in FJOA. Consistent with sequencing data, MMP7 was significantly downregulated in FJOA compared with controls. Since MMP12 was the most downregulated gene in FJOA, the biological functions of MMP12 can be investigated in future studies. In addition, TIMP3 and TIMP4 were found to be upregulated in FJOA. Elevated TIMPs further inactivate MMPs and influence the dynamics of the extracellular matrix ([@b35-etm-0-0-8488]).

In contrast with the present observations, many members of the MMP family were upregulated and/or activated in many other forms of osteoarthritis ([@b36-etm-0-0-8488]). The contradictory results implied that the molecular changes in joint tissues in osteoarthritis might be tissue-specific. Kim *et al* ([@b39-etm-0-0-8488]) reported that MMP1, MMP3 and MMP13 were upregulated in human degenerative facet joint tissues, however, MMP3 expression was downregulated in the present study. Aside from the differences in the collection of human facet joint tissues and the classification of FJOA, another difference was that the current study focused on the Chinese population while the study performed by Kim *et al* performed studies on tissues collected from an American population ([@b39-etm-0-0-8488]). Meta analyses could be conducted to investigate the association between genetic changes in FJOA and different populations. Further studies will be conducted to examine the protein expression and localization of these MMPs in FJOA.

Meanwhile, the expression levels of another group of metalloproteinases, ADAM proteins, were upregulated in FJOA. Similar to MMPs, ADAM proteins are also key modulators of the extracellular matrix ([@b40-etm-0-0-8488],[@b41-etm-0-0-8488]). Upregulated ADAM expression might execute opposite functions to downregulated MMPs in the breakdown and remodeling of the extracellular matrix by shedding transmembrane ligands of the epidermal growth factor (EGF) receptor and thus stimulate EGF receptor signaling. ADAM12 exhibits elevated expression levels in synovitis and post-inflammatory fibrosis of the synovial membrane in patients with early radiographic osteoarthritis ([@b42-etm-0-0-8488]). Polymorphisms of ADAM12, especially ADAM12 polymorphism rs3740199, are highly associated with knee osteoarthritis ([@b43-etm-0-0-8488],[@b44-etm-0-0-8488]). These previous studies indicated the involvement of ADAM12 in osteoarthritis and proposed the potential roles of ADAM in FJOA. Therefore, changes in ADAM expression and corresponding alterations in the extracellular matrix in FJOA also need to be further examined.

Overall, transcriptome sequencing and bioinformatics analysis determined the genetic changes of MMP-related genes in FJOA and demonstrated the implications of the extracellular matrix and MMPs in FJOA from a molecular aspect. The present results revealed the roles of the extracellular matrix and MMPs in FJOA, contributing to the understanding of the underlying mechanisms behind FJOA. This might contribute to the investigation of novel therapeutic targets for FJOA treatment.
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![Expression patterns of genes in healthy and lesioned facet joint tissues. The expression levels of genes are shown in a heatmap and indicated by a color bar. Red indicates upregulated genes while blue indicates downregulated genes.](etm-19-04-2475-g00){#f1-etm-0-0-8488}

![Top enriched GO categories in facet joint osteoarthritis. The ten most enriched GO biological processes, molecular functions and cellular components. Red represents GO biological processes, blue represents GO molecular functions and green represents GO cellular components. GO, gene ontology.](etm-19-04-2475-g01){#f2-etm-0-0-8488}

![Schematic diagram of the canonical signaling pathway 'inhibition of matrix metalloproteinases'. Differentially expressed genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases' are represented in red and green. Red indicates upregulated genes while green indicates downregulated genes. TIMP, tissue inhibitor of metalloproteinases; MMP, matrix metalloproteinase; RECK, reversion-inducing cysteine-rich protein with Kazal motifs; HSPG, basement membrane-specific heparan sulfate proteoglycan core protein; ADAM, disintegrin and metalloproteinase domain-containing protein; TSP2, thrombospondin-2; A2M, α-2-macroglobulin; TFPI2, tissue factor pathway inhibitor 2; LRP1, prolow-density lipoprotein receptor-related protein 1; MT1-MMP, matrix metallopeptidase 14 (membrane-inserted).](etm-19-04-2475-g02){#f3-etm-0-0-8488}

![Heatmap of differentially expressed genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases'. Red indicates upregulated genes while green indicates downregulated genes. CTRL, control group; FJOA, facet joint osteoarthritis; TIMP, tissue inhibitor of metalloproteinases; MMP, matrix metalloproteinase; RECK, reversion-inducing cysteine-rich protein with Kazal motifs; HSPG, basement membrane-specific heparan sulfate proteoglycan core protein; ADAM, disintegrin and metalloproteinase domain-containing protein; TSP2, thrombospondin-2; A2M, α-2-macroglobulin; TFPI2, tissue factor pathway inhibitor 2; LRP1, prolow-density lipoprotein receptor-related protein 1.](etm-19-04-2475-g03){#f4-etm-0-0-8488}

![Reverse transcription-quantitative PCR analysis of differentially expressed genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases'. The relative expression levels of MMP7, ADAM12, TIMP3 and TIMP4 were calculated. The red arrows indicate the expression trends of genes, as revealed by sequencing. Data were summarized from three independent experiments. ^\*^P\<0.05 vs. control. FJOA, facet joint osteoarthritis; MMP7, matrix metalloproteinase 7; ADAM12, disintegrin and metalloproteinase domain-containing protein 12; TIMP, tissue inhibitor of metalloproteinases.](etm-19-04-2475-g04){#f5-etm-0-0-8488}

###### 

Primer pairs for reverse transcription-quantitative PCR.

  Gene     Primer    Sequence (5\'-3\')
  -------- --------- ------------------------
  MMP7     Forward   AGCAGCTATGCAGCTGGCCGT
           Reverse   GCCCTGAGCCTGTTCCCACTGC
  ADAM12   Forward   TCTTGCTGCCGGATTTGTGGTT
           Reverse   AAGGGCGCACACACCTTAGTTT
  TIMP3    Forward   AGGACGCCTTCTGCAAC
           Reverse   CTCCTTTACCAGCTTCTTCC
  TIMP4    Forward   ACCTGTCCTTGGTGCAGA
           Reverse   TGTAGCAGGTGGTGATTTGG
  GAPDH    Forward   CCAAGGTCATCCATGACAAC
           Reverse   TGTCATACCAGGAAATGAGC

MMP7, matrix metalloproteinase 7; ADAM12, disintegrin and metalloproteinase domain-containing protein 12; TIMP, tissue inhibitor of metalloproteinases.

###### 

Top 10 upregulated and downregulated genes in FJOA.

  A, Upregulated                                                             
  ------------------ ----------- ----------- -------------------- ---------- --------------------------------------------
  CRHR1              0.022303    0.643232    4.85003              0.00463    Corticotropin releasing hormone receptor 1
  CSF3               0.230299    3.21825     3.80469              0.000259   Colony stimulating factor 3
  CRLF1              6.24624     81.3432     3.70296              0.000259   Cytokine receptor like factor 1
  DAW1               0.090234    1.12819     3.6442               0.022496   Dynein assembly factor with WD repeats 1
  HAS1               2.90011     35.0671     3.59594              0.000259   Hyaluronan synthase 1
  POSTN              23.7872     265.481     3.48035              0.000259   Periostin
  TMEM59L            0.181724    1.78416     3.29542              0.005947   Transmembrane protein 59 like
  PVRL4              0.170113    1.61362     3.24574              0.000259   Poliovirus receptor-related protein 4
  LINC00702          0.924058    8.50754     3.20269              0.002128   Long intergenic non-protein coding RNA 702
  HMCN2              0.158359    1.36891     3.11176              0.000259   Hemicentin 2
  B, Downregulated                                                           
  GeneID             CTRL_FPKM   FJOA_FPKM   log~2~ (FJOA/CTRL)   q-value    Description
  MMP12              1.5777      0.10857     -3.86112             0.013616   Matrix metallopeptidase 12
  HBG1               57.9551     4.16107     -3.79991             0.000259   Hemoglobin subunit γ1
  SPIC               2.63717     0.231806    -3.508               0.00394    Spi-c transcription factor
  TPSB2              8.40967     0.772965    -3.44357             0.000259   Tryptase β2 (gene/pseudogene)
  SEC14L3            0.596955    0.059692    -3.32201             0.007555   Sec14 like lipid binding 3
  PYHIN1             2.77976     0.280398    -3.30942             0.000259   Pyrin and hin domain family member 1
  CHI3L1             1078.35     114.902     -3.23036             0.000259   Chitinase 3 like 1
  CD19               1.2214      0.131175    -3.21897             0.004793   Cd19 molecule
  GP5                3.14407     0.360364    -3.12511             0.000259   Glycoprotein v platelet
  GPR15              1.43198     0.166889    -3.10106             0.033956   G protein-coupled receptor 15

FPKM, fragments per kilobase of transcript per million mapped reads; FJOA, facet joint osteoarthritis; CTRL, control.

###### 

Expression levels of differentially expressed genes in the canonical signaling pathway 'inhibition of matrix metalloproteinases'.

  GeneID   CTRL_FPKM   FJOA_FPKM   log~2~ (FJOA/CTRL)   q-value    Description
  -------- ----------- ----------- -------------------- ---------- ----------------------------------------------------------------------
  A2M      152.6       144.685     -0.07684             0.580386   α-2-macroglobulin
  ADAM10   23.1911     18.2402     -0.34645             0.00269    Disintegrin and metalloproteinase domain-containing protein 10
  ADAM12   5.90052     19.1302     1.69694              0.000259   Disintegrin and metalloproteinase domain-containing protein 12
  ADAM17   12.845      12.1117     -0.08481             0.581591   Disintegrin and metalloproteinase domain-containing protein 17
  HSPG2    79.3027     132.242     0.737738             0.000259   Basement membrane-specific heparan sulfate proteoglycan core protein
  LRP1     251.144     326.912     0.38039              0.012286   Prolow-density lipoprotein receptor-related protein 1
  MMP2     108.741     175.485     0.690452             0.000259   Matrix metalloproteinase 2
  MMP9     314.457     91.4777     -1.78137             0.000259   Matrix metalloproteinase 9
  MMP17    1.17006     1.48701     0.345823             0.353116   Matrix metalloproteinase 17
  MMP11    5.50944     8.16829     0.568128             0.001552   Matrix metalloproteinase 11
  MMP3     373.253     167.156     -1.15896             0.000259   Matrix metalloproteinase 3
  MMP19    6.38089     10.853      0.766262             0.000497   Matrix metalloproteinase 19
  MMP13    125.361     75.5355     -0.73086             0.000259   Matrix metalloproteinase 13
  MMP28    2.48386     4.40147     0.825399             0.026506   Matrix metalloproteinase 28
  MMP23B   0.04404     0.828743    4.23405              0.247905   Matrix metalloproteinase 23B
  MMP14    74.0875     118.202     0.673953             0.000259   Matrix metalloproteinase 14
  MMP24    1.21904     1.34362     0.14038              0.778023   Matrix metalloproteinase 24
  MMP8     37.9945     14.832      -1.35708             0.000259   Matrix metalloproteinase 8
  MMP1     6.78886     4.20773     -0.69013             0.493474   Matrix metalloproteinase 1
  MMP12    1.5777      0.10857     -3.86112             0.013616   Matrix metalloproteinase 12
  MMP15    1.65603     2.41486     0.54421              0.016667   Matrix metalloproteinase 15
  MMP16    9.42333     4.70063     -1.00338             0.000259   Matrix metalloproteinase 16
  MMP7     2.13341     1.03658     -1.04133             0.028971   Matrix metalloproteinase 7
  MMP25    6.06705     2.5246      -1.26494             0.000259   Matrix metalloproteinase 25
  RECK     9.33448     14.4833     0.633749             0.000259   Reversion-inducing cysteine-rich protein with Kazal motifs
  TFPI2    0.973482    0.789919    -0.30145             0.53558    Tissue factor pathway inhibitor 2
  TIMP1    322.419     227.107     -0.50557             0.000259   Tissue inhibitor of metalloproteinases 1
  TIMP2    216.411     377.86      0.804078             0.000259   Tissue inhibitor of metalloproteinases 2
  TIMP3    91.4082     261.077     1.51408              0.000259   Tissue inhibitor of metalloproteinases 3
  TIMP4    27.8848     57.9526     1.05539              0.000259   Tissue inhibitor of metalloproteinases 4
  TSP2     37.7629     73.7939     0.966534             0.000259   Thrombospondin-2

FPKM, fragments per kilobase of transcript per million mapped reads; FJOA, facet joint osteoarthritis; CTRL, control.
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